CAPITOL HILL STRATEGIES, LLC for PHRMA
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Legislation providing the President with Trade Promotion Authority Issues related to the Trans-Pacific Partnership trade agreement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M BRAIN | Asst. to the President, Dp.Chief Staff W&M Cmte |
| HEATHER MCHUGH | Legislative Director, Sen. Chuck Schumer |
| BEAU` SCHUYLER | LD-CongTanner, LD-CongMcIntyre,SA-CongRose |
| A. J. WOJCIAK | Senior Legislative Asst., Cong. Earl Pomeroy |
Copyright/Patent/Trademark CPT
Patent Reform Legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M BRAIN | Asst. to the President, Dp.Chief Staff W&M Cmte |
| HEATHER MCHUGH | Legislative Director, Sen. Chuck Schumer |
| BEAU` SCHUYLER | LD-CongTanner, LD-CongMcIntyre,SA-CongRose |
| A. J. WOJCIAK | Senior Legislative Asst., Cong. Earl Pomeroy |
Medicare/Medicaid MMM
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs) H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 (potential revenue raising and cost saving provisions) H. Con. Res. 27, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025 (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate, NIH funding provisions drawing funds from BIO/PhRMA industry government settlements, or other Medicare revenue raising provisions) S. Con. Res. 11, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025 (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate, NIH funding provisions drawing funds from BIO/PhRMA industry government settlements, or other Medicare revenue raising provisions) Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics. H.R. 1021, Protecting the Integrity of Medicare Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M BRAIN | Asst. to the President, Dp.Chief Staff W&M Cmte |
| HEATHER MCHUGH | Legislative Director, Sen. Chuck Schumer |
| BEAU` SCHUYLER | LD-CongTanner, LD-CongMcIntyre,SA-CongRose |
| A. J. WOJCIAK | Senior Legislative Asst., Cong. Earl Pomeroy |
Medical/Disease Research/Clinical Labs MED
Draft 21st Century Cures legislation under consideration by the House Energy & Commerce Committee (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies) S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M BRAIN | Asst. to the President, Dp.Chief Staff W&M Cmte |
| HEATHER MCHUGH | Legislative Director, Sen. Chuck Schumer |
| BEAU` SCHUYLER | LD-CongTanner, LD-CongMcIntyre,SA-CongRose |
| A. J. WOJCIAK | Senior Legislative Asst., Cong. Earl Pomeroy |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.